Secondhand smoke increases the risk of developing kidney stone disease

Chien-Heng Chen¹, Jia-In Lee², Jhen-Hao Jhan³,⁴,⁵, Yung-Chin Lee⁴,⁵, Jiun-Hung Geng³,⁴,⁵*, Szu-Chia Chen⁶,⁷,⁸,⁹, Chih-Hsing Hung⁸,⁹,¹⁰,¹¹ & Chao-Hung Kuo⁶,⁸,¹²

Research indicates smoking increases the risk of various kidney diseases, although the risk of developing kidney stone disease in non-smokers exposed to secondhand smoke is unknown. This study analyzed a total of 19,430 never-smokers with no history of kidney stone disease who participated in the Taiwan Biobank from 2008 to 2019. They were divided into two groups by secondhand smoke exposure; no exposure and exposure groups; the mean age of participants was 51 years, and 81% were women. Incident kidney stone development was observed in 352 (2.0%) and 50 (3.3%) participants in the no exposure and exposure groups during a mean follow-up of 47 months. The odds ratio (OR) of incident kidney stone was significantly higher in the exposure group than the no exposure group [OR, 1.64; 95% confidence interval (95% CI) 1.21 to 2.23]. Participants with > 1.2 h per week exposure were associated with almost twofold risk of developing kidney stones compared with no exposure (OR, 1.92; 95% CI 1.29 to 2.86). Our study suggests that secondhand smoke is a risk factor for development of kidney stones and supports the need for a prospective evaluation of this finding.

Kidney stone disease (KSD) is a global health problem. The lifetime risk of KSD in Taiwan is around 10%¹,², which is similar to North America and Europe¹. KSD is related to an increased risk of urinary tract infection and chronic kidney disease¹, and may also result in life-threatening diseases, including septicemia. Most stones form by a combination of genetics and environmental factors, so identifying modifiable factors and applying primary prevention is urgently needed to reduce the burden of KSD.

Smoking injures bodily health and causes damage to organs, including the kidneys⁵. Reports have shown that smoking is related to a higher risk of chronic kidney disease⁶, renal cancer⁷,⁸ and kidney stones⁹; however, little is known about the relationship between secondhand smoke (SHS) and kidney stone development. In addition, SHS could be comprised of even more toxic chemicals than those found in tobacco smoke, postulating that SHS could be harmful¹⁰,¹¹. It is important to understand the impact of SHS on kidney health, which could help enforce restrictions of smoking in our living environment. Based on previously limited results and the lack of a large cohort study follow-up on this issue, the aim of the present study was to investigate the association between SHS exposure and the risk of KSD in a longitudinal data of 19,430 participants from the Taiwan Biobank (TWB) study.

Results
Baseline characteristics. The baseline profiles of the 19,430 included participants are summarized in Table 1. The mean age was 51 ± 10 years; the majority of subjects (81%) were female; and a total of 17,905 (92%) subjects were included in the no exposure group. Among 1525 participants exposed to SHS, the median expo-
Sure hours per week were 1.2 (interquartile range 0.5 to 5). Participants were more exposed to SHS at home (n = 974, 65%) than at work (n = 598, 39%), with SHS exposure groups tending to have higher prevalence of alcohol consumption, lower prevalence of physical activity, were less married, and had higher body mass index (BMI) than those in the no exposure group.

**Association between SHS and the development of KSD.** A total of 402 participants (2.1% of the study population) had development of KSD during a mean follow-up duration of 47 ± 14 months. In univariate analysis, age, gender, married status, BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP), history of hypertension, history of dyslipidemia, serum hemoglobin, albumin, fasting glucose, hemoglobin A1c, triglyceride, high-density lipoprotein cholesterol and uric acid were significantly associated with the development of KSD (Table 2). The risk for incident kidney stone development was also significantly higher in the SHS exposure group than in the no exposure group (OR, 1.69; 95% CI 1.25 to 2.28, p value = 0.001). After adjusting for confounders, male gender, higher DBP, history of hypertension and SHS exposure were four independent risk factors for the development of KSD (Table 3). Comparing the SHS exposure group with the no exposure group, the OR for developing KSD showed significant increase in the exposure group (OR, 1.64; 95% CI 1.21 to 2.23, p value = 0.002). The association remained significant in models with additional adjustment for daily water intake in a subgroup of 8850 participants with adequate information (OR, 2.05; 95% CI 1.40 to 2.99, p value < 0.001) (Supplementary Table S1).

**Association between SHS frequency and the development of KSD.** To further evaluate the association between incident KSD and frequency of SHS exposure, we divided participants into three groups: no exposure, ≤ 1.2 h per week, and > 1.2 h per week according to the median exposure time. After adjusting for confounders, those exposed to SHS ≤ 1.2 h per week (OR, 1.40; 95% CI 0.90 to 2.18, p value = 0.138) or > 1.2 h per week (OR, 1.92; 95% CI 1.29 to 2.86, p value = 0.002) were associated with a higher risk for incident KSD compared with those not exposed to SHS (Table 4). Similar results were found when additional adjusting daily water intake (N = 8850) as shown in Supplementary Table S2.

### Table 1. Clinical characteristics of the study participants classified by exposure of secondhand smoke. BMI body mass index, BP blood pressure, eGFR estimated glomerular filtration rate, HDL high-density lipoproteins, LDL low-density lipoproteins.

| Characteristics                  | Total, n = 19,430 | Secondhand smoke exposure | No exposure, n = 17,905 | Exposure, n = 1525 | p value |
|----------------------------------|------------------|---------------------------|------------------------|-------------------|---------|
| **Demographic data**             |                  |                           |                        |                   |         |
| Age, yr                          | 51 ± 10          | 51 ± 10                   | 48 ± 10                | 0.387             |         |
| Women                            | 15,644 (81)      | 14,482 (81)               | 1162 (76)              | < 0.001           |         |
| BMI, kg/m²                       | 23.7 ± 3.5       | 23.7 ± 3.5                | 24.2 ± 3.8             | 0.001             |         |
| Alcohol status, ever             | 571 (3)          | 458 (3)                   | 113 (7)                | < 0.001           |         |
| Physical activity, yes           | 8987 (46)        | 8422 (47)                 | 565 (37)               | < 0.001           |         |
| Married, yes                     | 17,693 (91)      | 16,337 (91)               | 1356 (89)              | 0.002             |         |
| Systolic BP, mm Hg               | 117 ± 18         | 116 ± 18                  | 116 ± 18               | 0.363             |         |
| Diastolic BP, mm Hg              | 72 ± 11          | 72 ± 11                   | 72 ± 11                | 0.118             |         |
| **Comorbidities**                |                  |                           |                        |                   |         |
| Hypertension                     | 2171 (11)        | 2012 (11)                 | 162 (11)               | 0.465             |         |
| Diabetes                         | 896 (5)          | 818 (5)                   | 72 (5)                 | 0.784             |         |
| Dyslipidemia                     | 1260 (7)         | 1170 (7)                  | 90 (6)                 | 0.335             |         |
| **Laboratory data**              |                  |                           |                        |                   |         |
| eGFR, ml/min per 1.73 m²         | 105 ± 24         | 105 ± 24                  | 106 ± 25               | 0.085             |         |
| Hemoglobin, g/dl                 | 13.4 ± 1.5       | 13.4 ± 1.4                | 13.4 ± 1.5             | 0.003             |         |
| Albumin, g/dl                    | 4.5 ± 0.2        | 4.5 ± 0.2                 | 4.6 ± 0.2              | 0.004             |         |
| Fasting glucose, mg/dl           | 95 ± 19          | 95 ± 19                   | 96 ± 22                | < 0.001           |         |
| Hemoglobin A1c, %                | 5.7 ± 0.7        | 5.7 ± 0.7                 | 5.7 ± 0.9              | 0.001             |         |
| Total cholesterol, mg/dl         | 196 ± 36         | 196 ± 36                  | 194 ± 36               | 0.489             |         |
| Triglyceride, mg/dl              | 107 ± 75         | 106 ± 73                  | 110 ± 92               | 0.001             |         |
| HDL cholesterol, mg/dl           | 56 ± 13          | 56 ± 13                   | 55 ± 13                | 0.152             |         |
| LDL cholesterol, mg/dl           | 121 ± 32         | 122 ± 32                  | 121 ± 31               | 0.881             |         |
| Uric acid, mg/dl                 | 5.2 ± 1.3        | 5.2 ± 1.3                 | 5.4 ± 1.4              | < 0.001           |         |
### Table 2. Parameters associated with incident kidney stone in univariable binary logistic analysis in all study participants (n = 19,430). BP blood pressure, eGFR estimated glomerular filtration rate, HDL high-density lipoproteins, LDL low-density lipoproteins, CI confidence interval.

| Parameters                                      | Odds ratio (95% CI) | p     |
|-------------------------------------------------|---------------------|-------|
| Age (per 1 year)                                 | 1.011 (1.001 to 1.021) | 0.032 |
| Women (vs. men)                                  | 0.415 (0.337 to 0.510) | < 0.001 |
| Body mass index (per 1 kg/m²)                    | 1.065 (1.038 to 1.092) | < 0.001 |
| Alcohol status, ever (vs. never)                 | 1.472 (0.899 to 2.411) | 0.124 |
| Physical activity, yes (vs. no)                  | 1.011 (0.829 to 1.232) | 0.915 |
| Married, yes (vs. no)                            | 1.631 (1.068 to 2.492) | 0.024 |
| Systolic blood pressure (per 1 mmHg)             | 1.013 (1.008 to 1.018) | < 0.001 |
| Diastolic blood pressure (per 1 mmHg)            | 1.031 (1.022 to 1.040) | < 0.001 |
| Hypertension, yes (vs. no)                       | 1.913 (1.486 to 2.462) | < 0.001 |
| Diabetes mellitus, yes (vs. no)                  | 1.271 (0.830 to 1.947) | 0.270 |
| Dyslipidemia, yes (vs. no)                       | 1.753 (1.271 to 2.418) | 0.001 |
| eGFR (per 1 ml/min/1.73 m²)                      | 0.996 (0.992 to 1.001) | 0.085 |
| Hemoglobin (per 1 g/dl)                          | 1.307 (1.216 to 1.403) | < 0.001 |
| Albumin (per 1 g/dl)                             | 1.851 (1.197 to 2.862) | 0.006 |
| Fasting glucose (per 1 g/dl)                     | 1.005 (1.001 to 1.009) | 0.009 |
| Hemoglobin A1c (per 1%)                          | 1.141 (1.028 to 1.267) | 0.013 |
| Total cholesterol (per 1 mg/dl)                  | 1.001 (0.998 to 1.003) | 0.704 |
| Triglyceride (per 1 mg/dl)                       | 1.002 (1.001 to 1.002) | < 0.001 |
| HDL cholesterol (per 1 mg/dl)                    | 0.983 (0.975 to 0.991) | < 0.001 |
| LDL cholesterol (per 1 mg/dl)                    | 1.003 (0.999 to 1.006) | 0.109 |
| Uric acid (per 1 mg/dl)                          | 1.228 (1.146 to 1.315) | < 0.001 |
| Secondhand smoke exposure, yes (vs. no)          | 1.690 (1.251 to 2.284) | 0.001 |

### Table 3. Parameters associated with incident kidney stone in multivariate binary logistic analysis in all study participants (n = 19,430). Multivariable model: adjustment for age, sex, marital status, body mass index, systolic blood pressure, diastolic blood pressure, history of hypertension, history of dyslipidemia, hemoglobin, Hemoglobin A1c, serum fasting glucose, triglyceride, high-density lipoprotein cholesterol, serum albumin, and serum uric acid. BP blood pressure, eGFR estimated glomerular filtration rate, HDL high-density lipoproteins, LDL low-density lipoproteins, CI confidence interval.

| Parameters                                      | Odds ratio (95% CI) | p     |
|-------------------------------------------------|---------------------|-------|
| Age (per 1 year)                                 | 1.005 (0.993 to 1.017) | 0.385 |
| Women (vs. men)                                  | 0.585 (0.438 to 0.782) | < 0.001 |
| Body mass index (per 1 kg/m²)                    | 1.023 (0.991 to 1.057) | 0.161 |
| Alcohol status, ever (vs. never)                 | -                   | -     |
| Physical activity, yes (vs. no)                  | -                   | -     |
| Married, yes (vs. no)                            | 1.530 (0.983 to 2.381) | 0.060 |
| Systolic blood pressure (per 1 mmHg)             | 0.995 (0.986 to 1.004) | 0.297 |
| Diastolic blood pressure (per 1 mmHg)            | 1.021 (1.007 to 1.035) | 0.084 |
| Hypertension, yes (vs. no)                       | 1.383 (1.037 to 1.845) | 0.028 |
| Diabetes mellitus, yes (vs. no)                  | -                   | -     |
| Dyslipidemia, yes (vs. no)                       | 1.377 (0.979 to 1.937) | 0.066 |
| eGFR (per 1 ml/min/1.73 m²)                      | -                   | -     |
| Hemoglobin (per 1 g/dl)                          | 1.086 (0.991 to 1.190) | 0.079 |
| Albumin (per 1 g/dl)                             | 1.178 (0.736 to 1.885) | 0.495 |
| Fasting glucose (per 1 g/dl)                     | 0.999 (0.991 to 1.007) | 0.824 |
| Hemoglobin A1c (per 1%)                          | 1.027 (0.831 to 1.269) | 0.806 |
| Total cholesterol (per 1 mg/dl)                  | -                   | -     |
| Triglyceride (per 1 mg/dl)                       | 1.000 (0.999 to 1.002) | 0.432 |
| HDL cholesterol (per 1 mg/dl)                    | 0.998 (0.989 to 1.007) | 0.686 |
| LDL cholesterol (per 1 mg/dl)                    | -                   | -     |
| Uric acid (per 1 mg/dl)                          | 0.998 (0.914 to 1.090) | 0.969 |
| Secondhand Smoke Exposure, yes (vs. no)          | 1.643 (1.209 to 2.234) | 0.002 |
of participants who were exposed to SHS was 26.5% in 2008\(^1\), and as a result of the amendment to the Tobacco policy makers to take action on protecting the population against exposure to SHS. In Taiwan, the proportion of cardiovascular diseases\(^1\), respiratory diseases\(^1\), lung cancer\(^1\), and kidney diseases\(^1\). A large screened population is the first study to demonstrate a possible influence of SHS on the development of KSD. To our knowledge, this cohort in Taiwan with information about lifestyle, medical history and exposed environments, which provide an ideal platform for research to explore the causes of common diseases, including KSD. To our knowledge, this is the first study to demonstrate a possible influence of SHS on the development of KSD.

Previous, evidence reveals that exposure to SHS can cause a variety of health issues in non-smokers, such as cardiovascular diseases\(^1\), respiratory diseases\(^1\), lung cancer\(^1\), and kidney diseases\(^1\). A large screened population of more than 130,000 healthy Asian men showed a history of SHS exposure was associated with a higher risk for chronic kidney disease\(^7\). In addition, Omoloja et al. found that SHS exposure was an independent risk factor for nephrotic range proteinuria in children (OR, 2.64; 95% CI 1.08 to 6.42)\(^1\). These findings indicate that exposure to SHS might cause glomerular dysfunction and a decreased output of urine, both of which might induce urolithiasis\(^1\)–\(^3\).

Consistent with the hypothesis that SHS exposure could injure the kidneys, an association between SHS and KSD was demonstrated, with the finding pointing to the fact that SHS could be as dangerous as smoking in developing kidney stones\(^9\)–\(^11\). Liu et al. analyzed 354 cases and 354 age- and sex-matched healthy controls and found current cigarette smoking was an independent risk factor for the development of kidney stones (OR 1.66; 95% CI 1.11 to 2.50)\(^1\). Similar results were seen among 102 cases in Iran (OR 2.06; 95% CI 1.06 to 4.01)\(^9\), and 181 cases in Japan (OR 4.29; 95% CI 2.68 to 6.86)\(^2\). In line with these studies, this study found that non-smokers exposed to SHS had a significant increase of nephrolithiasis risk in a multivariate binary logistic analysis (OR 1.64; 95% CI 1.21 to 2.23). Although, there is no direct comparison of the risk of developing kidney stones between smokers and non-smokers with SHS exposure, the toxic chemicals inhaled by first-hand smokers and secondhand smokers are similar, and the adverse health effects are similar as well\(^5\).

In the present study, a subgroup analysis stratified by frequency of SHS exposure found non-smokers exposed to SHS \(\leq 1.2\) h per week had a 1.4-fold higher risk of developing kidney stones than those not exposed; moreover, participants who were exposed for more than 1.2 h per week were associated with an almost twofold risk of developing kidney stones compared with no exposure. The current literature has shown there is no risk-free level of SHS exposure\(^6\)–\(^9\). Studies also revealed that even brief (minutes to hours) exposure can be as harmful to health as chronic active smoking\(^2\)–\(^4\). Our findings suggest that even infrequent exposure to SHS could lead to a higher rate of stone formation, which may be helpful for public health and clinical care. If SHS is related to subsequent kidney stone diseases, a comprehensive smoke-free policy could be adopted to prevent the development of stones to protect non-smokers, and this is the only way to fully protect the health of this group\(^1\).

Although the exact mechanism of SHS exposure-associated renal stone formation is undetermined, it is speculated that exposure to SHS might produce similar renal damage to that seen among active smokers. Based on previous research, non-smokers exposed to SHS will inhale 80% of airborne chemicals from smoke and the quantities of absorption are similar to those of smokers\(^6\). There is also evidence that elevated blood nicotine and cadmium levels have been observed in the population with secondhand smoke exposure\(^10\)–\(^13\). Several studies have shown that increased serum cadmium is related to urinary tract stone formation\(^15\)–\(^17\). Besides, nicotine from cigarette smoking could increase serum vasopressin levels, resulting in a decrease in urine output, which is a risk factor for stone formation\(^15\)–\(^17\). Another possible mechanism is that smoking might decrease the level of calcium excretion in urine, and lower urinary calcium level is associated with increased odds of kidney stone formation\(^16\). Smoking can also induce oxidative stress in the kidney and lead to renal injury\(^18\)–\(^20\), with such damage further increasing the nucleation, aggregation and retention of crystals, and promoting the formation of stones in the kidney\(^19\)–\(^20\).

The strength of this study is being the first to demonstrate a possible influence of SHS on incident KSD. This is also a large study performed in a community-based cohort, with detailed information and regular

| Secondhand smoke frequency | No. of cases (%) | Number at risk | Adjusted odds ratio (95% CI) | \(p\) value |
|-----------------------------|-----------------|---------------|-----------------------------|-----------|
| No exposure                 | 352 (2.0)       | 17,905        | 1.00 (Reference)            | –         |
| \(\leq 1.2\) h per week     | 22 (2.8)        | 786           | 1.40 (0.90 to 2.18)         | 0.138     |
| > 1.2 h per week            | 28 (3.8)        | 739           | 1.92 (1.29 to 2.86)         | 0.002     |

Table 4. Relative risk for incident kidney stone disease according to frequency of secondhand smoke.

Multivariable model: adjustment for age, sex, marital status, body mass index, systolic blood pressure, diastolic blood pressure, history of hypertension, history of dyslipidemia, hemoglobin, Hemoglobin A1c, serum fasting glucose, triglyceride, high-density lipoprotein cholesterol, serum albumin, and serum uric acid. CI confidence interval.

Discussion

In this longitudinal study of a representative sample of the Taiwan population, SHS was significantly associated with a higher risk of incident KSD after adjustment of covariates. In addition, participants with > 1.2 h per week exposure were associated with almost twofold risk of developing kidney stones compared with no exposure.

According to the World Health Organization (WHO), 40% of children, 35% of female non-smokers, and 33% of male non-smokers were exposed to SHS worldwide in 2004\(^2\). Moreover, convincing evidence claims that exposure to SHS causes more than 880,000 deaths worldwide each year\(^2\). These findings have induced policy makers to take action on protecting the population against exposure to SHS. In Taiwan, the proportion of participants who were exposed to SHS was 26.5% in 2008\(^2\), and as a result of the amendment to the Tobacco Hazards Prevention Act in 2009, the proportion decreased substantially\(^4\), being 8% in our cohort. Although the number of individuals exposed to SHS decreased between 1990 and 2016\(^5\), there is still an urgent need to understanding the harmful effects associated with SHS. Our research builds upon a large-scale community-based cohort in Taiwan with information about lifestyle, medical history and exposed environments, which provide an ideal platform for research to explore the causes of common diseases, including KSD. To our knowledge, this is the first study to demonstrate a possible influence of SHS on the development of KSD.

In this longitudinal study of a representative sample of the Taiwan population, SHS was significantly associated with a higher risk of incident KSD after adjustment of covariates. In addition, participants with > 1.2 h per week exposure were associated with almost twofold risk of developing kidney stones compared with no exposure.
follow-up. Despite these strengths, several limitations should be noted. Firstly, the existence of nephrolithiasis was obtained via questionnaire, without radiologic verification; however, this substitution has been validated in other studies. Secondly, information was lacking on dietary data, but these factors are difficult to record in detail and change a lot even in individual-by-individual. Thirdly, information about type of kidney stone was lacking, but the majority of stones would be calcium oxalate stones; and fourthly, there was no subgroup of children or pregnant women, because this cohort only collected adult participants, and did not mention the status of pregnancy. Finally, measurements of the toxic chemicals from SHS exposure were not performed.

In conclusion, this study suggests that SHS is a risk factor for development of kidney stones and supports the need for a prospective evaluation of this finding. Public health implications include enhancing smoke-free rules and educating the public about the adverse effects of SHS.

Methods

Data source and study population. This study used data from the TWB, a large-scale community-based research database comprised of cancer-free volunteers aged between 30 and 70 years enrolled through 29 recruitment centers in Taiwan since 2008. The detailed methods and profile concerning the development of TWB has been described previously. A total of 27,209 participants with adequate baseline and long-term follow-up data were enrolled in the present study. Initially, participants with information on KSD were screened, then those with known underlying KSD (N = 1825) were excluded. Those with missing smoking data (N = 15), body mass index (N = 16), alcohol status (N = 9), physical activity status (N = 6), or serum creatinine (N = 18), and participants who were active or ex-smokers (N = 5890) were also excluded. The final analysis included 19,430 participants (Supplementary Figure S1). Participants underwent serial physical examination, biospecimen collection, and questionnaire surveys every 2 to 4 years from 2008 to 2019. The presence of a history of KSD was surveyed by a questionnaire. Written informed consent was obtained in all cases and all investigations were conducted according to the Declaration of Helsinki. This study was approved by the Institutional Review Board of Kaohsiung Medical University Hospital (KMUHIRB-E(I)-20190398).

Smoking and SHS assessments. Firstly, participants were classified as "never-smokers", "ex-smokers", and "active smokers" by self-reported questionnaires. Among never-smokers, they were asked the following question: "Have you been exposed to SHS?". Never-smokers who were exposed to SHS were assigned as the exposure group, others were allocated as the no exposure group. Participants in the exposure group were further asked "How many hours per week have you been exposed to SHS?". According to the exposure time, we divided participants into "no exposure", "≤ 1.2 h per week", and "> 1.2 h per week." The cut point of 1.2 h per week was based on the median exposure time in our cohort.

Study outcome. In the present study, the primary end point was the development of self-reported KSD. As stated above, participants with a history of KSD were excluded. All subjects in this study had no history of kidney stone formation at baseline. During the follow-up, subjects were asked, "Have you had a kidney stone?" The development of kidney stone was defined as the subject responding "Yes" to this question. The association between SHS exposure and incident KSD was evaluated.

Statistical analyses. Participants in the present study were stratified into no exposure and exposure groups. Clinical characteristics were presented as percentages for categorical variables, and mean ± standard deviation for continuous variables, while statistical significance of differences among categorical variables was assessed using Pearson χ² test and among continuous variables were assessed using independent t-test. Logistic regression analyses were used to analyze the association of SHS exposure with incident KSD with ORs and 95% CIs before and after adjusting for confounders including age, sex, alcohol status, marital status, physical activity, BMI, SBP, DBP, history of hypertension, history of diabetes, history of dyslipidemia, hemoglobin, Hemoglobin A1c, serum fasting glucose, total cholesterol, triglyceride, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, serum albumin, serum uric acid, and estimated glomerular filtration rate. All analyses were carried out using SPSS 20.0 (IBM Corp, Armonk, NY, USA) and R version 3.6.2 (R Foundation for Statistical Computing, Wien, Austria) and a p value of < 0.05 was considered statistically significant.

Received: 25 June 2021; Accepted: 23 August 2021
Published online: 06 September 2021

References

1. Huang, W. Y. et al. Epidemiology of upper urinary tract stone disease in a Taiwanese population: A nationwide, population based study. J. Urol. 189(6), 2158–2163 (2013).
2. Lee, Y. H. et al. Epidemiological studies on the prevalence of upper urinary calculi in Taiwan. Urol. Int. 68(3), 172–177 (2002).
3. Romero, V., Akinpar, H. & Assimos, D. G. Kidney stones: A global picture of prevalence, incidence, and associated risk factors. Rev Urol. 12(2–3), e86–e96 (2010).
4. Rule, A. D. et al. Kidney stones and the risk for chronic kidney disease. Clin. J. Am. Soc. Nephrol. CJASN. 4(4), 804–811 (2009).
5. Orth, S. R. & Hallan, S. I. Smoking: A risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients—Absence of evidence or evidence of absence?. Clin. J. Am. Soc. Nephrol. 3(1), 226 (2008).
6. Xia, J. et al. Cigarette smoking and chronic kidney disease in the general population: A systematic review and meta-analysis of prospective cohort studies. Nephrol. Dial. Transpl. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Renal Assoc. 32(3), 475–487 (2017).
9. Tamadon, M. R., Nassaji, M. & Ghorbani, R. Cigarette smoking and nephrolithiasis in adult individuals. *Int. J. Cancer* 114(1), 101–108 (2005).

10. Schick, S. & Glantz, S. Philip Morris toxicological experiments with fresh sidestream smoke: More toxic than mainstream smoke. *Tob. Control* 14(6), 396–404 (2005).

11. Tong, E. K. & Glantz, S. A. Tobacco industry efforts undermining evidence linking secondhand smoke with cardiovascular disease. *Circulation* 116(16), 1845–1857 (2007).

12. Oberm, M., Jaakkola, M. S., Woodward, A., Peruga, A. & Prüss-Ustün, A. Worldwide burden of disease from exposure to secondhand smoke: A retrospective analysis of data from 192 countries. *Lancet (London, England)* 377(9760), 139–146 (2011).

13. Tsai, Y. W., Chang, L. C., Sung, H. Y., Hu, T. W. & Chiou, S. T. The impact of smoke-free legislation on reducing exposure to secondhand smoke: Differences across gender and socioeconomic groups. *Tob. Control* 24(1), 62–69 (2015).

14. Hobe, J. H. et al. Secondhand smoke and CKD. *Clim. J. Am. Soc. Nephrol. CJASN* 14(4), 515–522 (2019).

15. Omojola, A. et al. Secondhand smoke exposure is associated with proteinuria in children with chronic kidney disease. *Pediatr. Nephrol.* 28(8), 1243–1251 (2013).

16. Worcester, E. M. & Coe, F. L. Clinical practice. Calcium kidney stones. *Ann. Intern. Med.* 158(9), 694–705 (2013).

17. Armstrong, L. E., Munoz, C. X. & Armstrong, E. M. Distinguishing low and high water consumers—A paradigm of disease risk. *Tob. Control* 25(6), 587–593 (2016).

18. Durak, I., Sahin, A. & Perk, H. Smoking, hair cadmium and urinary tract stones. *Urol. Res.* 39(5), 217–223 (2011).

19. Barnoya, J. & Glantz, S. A. Cardiovascular effects of secondhand smoke: Nearly as large as smoking. *J. Am. Heart Assoc.* 5(9), e003588 (2016).

20. Hamano, S. et al. Kidney stone disease and risk factors for coronary heart disease. *Int. J. Urol. Off. J. Ipn. Urol. Assoc.* 12(10), 859–863 (2005).

21. Semeniuk, M., Bartlett, S. J., Noureldin, Y. A., Andersen, R. E. & Andonian, S. Leisure time physical activity, smoking and risk of second hand smoking: Differences across gender and socioeconomic groups. *Nicotine Tob. Res.* 8(10), 705–712 (2006).

22. Seppanen, L., Antila, M., Huhma, H., Leinonen, E., Vartiainen, E. & Nissinen, A. Overall causes of death and risk factors for heart disease in women. *Ann. N. Y. Acad. Sci.* 1033, 178–190 (2005).

23. Robert, M. et al. Circadian variations in the risk of urinary calcium oxalate stone formation. *Br. J. Urol.* 74(3), 294–297 (1994).

24. McLean, D. et al. Effects of smoking and physical exercise on platelet free cytosolic calcium in healthy normotensive volunteers. *J. Hypertens.* 7(3), 211–216 (1989).

25. Othman, S. N. et al. The association between smoking and nephrolithiasis in Han Chinese in the modern Taiwanese population based on 10,000 participants in the Taiwan Biobank project. *Hum. Mol. Genet.* 25(24), 5321–5331 (2016).

Acknowledgements

This work was supported partially by the Research Center for Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan, by Kaohsiung Medical University Research Center Grant (KMU-TC109A01-1) and by Kaohsiung Municipal Siaogang Hospital (S-108-017).
Author contributions
J.-H.G., S.-C.C.: conception and design; J.-H.G., J.-I.L., S.-C.C.: acquisition of data; all authors: analysis and interpretation of data; C.-H.C., J.-H.G., S.-C.C.: drafting of the manuscript; all authors: critical revision of the manuscript for important intellectual content; J.-H.G., J.-I.L., S.-C.C.: statistical analysis; J.-I.L., S.-C.C., C.-H.H., C.-H.K.: administrative, technical, or material support; S.-C.C., C.-H.H., C.-H.K.: supervision; none: other (specify).

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-97254-y.

Correspondence and requests for materials should be addressed to J.-H.G.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021